🏛️ Verified NIH Record • Updated 2026-10-22

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (NCT07357727)

RECRUITING Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Who can join: Review the eligibility criteria below.

Location: Yale University School Of Medicine — New Haven, Connecticut

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (53 Sites)

  • Yale University School Of Medicine — New Haven, Connecticut
  • Winship Cancer Institute of Emory University — Atlanta, Georgia
  • Summit Medical Group Oncology — Berkeley Heights, New Jersey
  • The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
  • Novartis Investigative Site — Buenos Aires, Buenos Aires F.D.
  • Novartis Investigative Site — CABA,
  • Novartis Investigative Site — Capital Federal,
  • Novartis Investigative Site — Córdoba,
  • Novartis Investigative Site — Clayton, Victoria
  • Novartis Investigative Site — Hefei, Anhui
  • Novartis Investigative Site — Guangzhou, Guangdong
  • Novartis Investigative Site — Guangzhou, Guangdong
  • Novartis Investigative Site — Wuhan, Hubei
  • Novartis Investigative Site — Nanjing, Jiangsu
  • Novartis Investigative Site — Nantong, Jiangsu
  • Novartis Investigative Site — Changchun, Jilin
  • Novartis Investigative Site — Yantai, Shandong
  • Novartis Investigative Site — Kunming, Yunnan
  • Novartis Investigative Site — Hangzhou, Zhejiang
  • Novartis Investigative Site — Wenzhou, Zhejiang
  • Novartis Investigative Site — Beijing,
  • Novartis Investigative Site — Chongqing,
  • Novartis Investigative Site — Fuzhou,
  • Novartis Investigative Site — Shanghai,
  • Novartis Investigative Site — Shenyang,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗